Tone mix
Week by week 52 weeks
Share of Sagimet Biosciences Inc. Series A Common Stock's 106 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 15, 2025 · tone -100Sagimet Biosciences (NASDAQ:SGMT) Downgraded to Sell Rating by Wall Street Zen-100
- Week of Sep 22, 2025 · tone +100Sagimet Biosciences (NASDAQ:SGMT) Upgraded at Wall Street Zen+85
- Week of Oct 12, 2026 · tone 0Recent Investment Analysts' Ratings Updates for Sagimet Biosciences (SGMT)-66
- Week of Mar 16, 2026 · tone +100Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Analysts+61
- Week of Mar 23, 2026 · tone +100Analysts Remain Optimistic in Sagimet Biosciences (SGMT)'s Outlook Following Q4 and Full-Year 2025 Results+56
- Week of Sep 7, 2026 · tone +100Sagimet Biosciences (NASDAQ:SGMT) Upgraded to Strong-Buy at Cantor Fitzgerald+56
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Sagimet Biosciences Inc. Series A Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 4 | +49 |
| Last 30 sessions | 13 | +53 |
| Last 90 sessions | 30 | +49 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
2 headlines, average tone +48: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.rttnews.com · 1 outletSagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne PatientsPositive
- www.tickerreport.com · 1 outletSagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Average Target Price of $26.63Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne Patients | www.rttnews.com | 1 | Positive |
| Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Average Target Price of $26.63 | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletSagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe AcnePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 2 outletsRecent Investment Analysts' Ratings Updates for Sagimet Biosciences (SGMT)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Recent Investment Analysts' Ratings Updates for Sagimet Biosciences (SGMT) | www.tickerreport.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 5, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletSagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial LaunchPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Sagimet Biosciences Inc. Series A Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.